Monte Rosa Therapeutics develops molecular glue degrader medicines for serious diseases using its QuEEN discovery engine, which combines AI-guided chemistry, chemical libraries, structural biology and proteomics. The company’s news centers on clinical and preclinical updates for programs including MRT-8102, a NEK7-directed degrader for inflammatory disease biology; MRT-2359, a GSPT1-directed degrader studied in metastatic castration-resistant prostate cancer; and MRT-6160, a VAV1-directed degrader for immune-mediated diseases.
Recurring developments also include oncology discovery work such as cyclin E1-directed and CDK2-directed degrader programs, clinical supply and pharmaceutical collaboration activity, quarterly financial results, equity awards, capital resources and public-company governance updates.
Monte Rosa Therapeutics (GLUE) presented preclinical findings showing MRT-8102 reduced inflammatory activity in human experimental systems and a rabbit gout model. MRT-8102 degrades NEK7, a protein required to activate the NLRP3 inflammatory complex. It reduced crystal-triggered caspase-1 activity in human macrophages and suppressed release of the inflammatory protein IL-1β in stimulated blood from donors with and without gout.
In rabbits, oral MRT-8102 reduced joint swelling and improved ultrasound-assessed joint scores versus vehicle controls. It also reduced synovial-fluid C-reactive protein and induced NEK7 degradation in spleens. These are preclinical results, not outcomes in patients with gout. Monte Rosa expects its Phase 2 GEMINI-1 study to begin in Q4 2026, with initial data in H2 2027. The study will assess prevention of recurrent flares after acute flare management.
Monte Rosa Therapeutics (Nasdaq: GLUE) reported third-quarter 2026 net income of $3.1 million as collaboration revenue increased and clinical programs advanced. Revenue was $54.4 million, versus $12.8 million a year earlier, including a $50 million Novartis milestone. The prior-year quarter had a $27.1 million net loss.
MRT-8102 Phase 1 results showed approximately 80% to 90% median target-protein reduction across all three doses, with no serious adverse events. Monte Rosa expects three Phase 2 starts through H1 2027. MRT-2359 entered Phase 2, with data expected in 2027. Novartis initiated two MRT-6160 studies, triggering $87.5 million in milestones. Cash, restricted cash and marketable securities totaled $582.6 million at September 30, excluding those milestone receipts; Monte Rosa expects funding into 2029. Operating use primarily drove a $43.4 million quarterly decline in these funds.
Monte Rosa Therapeutics (Nasdaq: GLUE) granted inducement equity awards to four newly hired non-executive employees, effective November 2, 2026.
The awards comprise options to purchase 33,775 shares at an exercise price of $10.63 per share, equal to the Nasdaq closing price on the grant date, and restricted stock units covering 7,400 shares. Both awards vest over four years, subject to continued service. The independent compensation committee approved the awards under the 2026 Inducement Plan, outside stockholder-approved equity incentive plans, as inducements to employment under Nasdaq Listing Rule 5635(c)(4).
Monte Rosa Therapeutics (GLUE) management will participate in four investor conference fireside chats in November and December 2026.
The schedule includes Guggenheim on November 9 at 8:00 a.m. ET, UBS on November 16 at 12:00 p.m. GMT, Jefferies on November 17 at 10:00 a.m. GMT, and Piper Sandler on December 1 at 3:30 p.m. ET. Webcasts will be available through the company's website, with archives available for 30 days following the presentations.
Monte Rosa Therapeutics (GLUE) will receive a $37.5 million milestone payment following Novartis’s initiation of a second Phase 2 study of MRT-6160. The payment is tied to the first patient visit in the trial involving participants with active moderate to severe psoriatic arthritis. The Phase 2a/b study will evaluate efficacy, safety, tolerability and dose response. It follows a Sjögren’s disease trial initiated in August.
Under their exclusive worldwide license agreement, Novartis conducts and funds Phase 2 development. Monte Rosa remains eligible for additional Phase 2 initiation milestones under an agreement providing up to $2.1 billion in development, regulatory and sales milestones. Monte Rosa will co-fund any Phase 3 development and share 30% of U.S. manufacturing and commercialization profits and losses, with eligibility for tiered royalties on ex-U.S. net sales.
Monte Rosa Therapeutics (GLUE) granted inducement equity awards to five newly hired non-executive employees, effective October 1, 2026.
The awards include options to purchase 86,725 shares at an exercise price of $11.26 per share, equal to Nasdaq’s closing price on the grant date, and restricted stock units covering 19,150 shares. Both awards vest over four years, subject to continued service. The independent compensation committee approved the awards under the 2026 Inducement Plan, outside stockholder-approved equity incentive plans, in accordance with Nasdaq Listing Rule 5635(c)(4).
Monte Rosa Therapeutics (GLUE) reported biomarker reductions and safety results for MRT-8102 in its GFORCE-1 Phase 1 cardiovascular-risk study. The trial randomized 108 obese subjects with elevated cardiovascular disease risk to 5 mg, 20 mg or 40 mg once daily, or placebo, for four weeks, followed by four weeks of safety follow-up. Median NEK7 protein reductions were approximately 80 to 90% across all doses. Several inflammatory markers fell to levels comparable to healthy-volunteer baselines; median hsCRP fell 85% and lipoprotein(a) fell 24%.
No serious adverse events occurred; treatment-emergent adverse events affected 33% of treated participants versus 30% on placebo. Monte Rosa expects to start gout Phase 2 testing in Q4 2026 or Q1 2027 and coronary artery disease and hidradenitis suppurativa studies in H1 2027. The coronary study design awaits regulatory feedback and supporting long-term preclinical toxicology work.
Monte Rosa Therapeutics (GLUE) will present MRT-8102 GFORCE-1 Phase 1 study results during a webcast on October 1, 2026. The presentation begins at 8:00 a.m. ET and covers subjects with elevated cardiovascular disease risk. It will review safety and activity data across multiple dose levels following 4 weeks of treatment, including effects on drivers of atherosclerotic cardiovascular disease.
Monte Rosa Therapeutics (GLUE) announced that collaborator Novartis has initiated a Phase 2 clinical study of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease, triggering a $50 million milestone payment to Monte Rosa.
The Phase 2a/b randomized, double-blind, placebo-controlled, multi-center trial will evaluate up to 52 weeks of MRT-6160 treatment to assess efficacy, safety and tolerability and to support Phase 3 dose selection. The study, titled “A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease,” is listed as NCT07737743 on ClinicalTrials.gov.
Under a global exclusive license, Novartis holds worldwide rights and funds Phase 2 development, while Monte Rosa remains eligible for up to $2.1 billion in development, regulatory and sales milestones and a 30% share of U.S. profits and losses for MRT-6160, plus tiered ex-U.S. royalties.
Monte Rosa Therapeutics (GLUE) granted inducement equity awards to six newly hired non-executive employees under its 2026 Inducement Plan. The grants include non-qualified stock options to purchase an aggregate of 31,145 shares of common stock at an exercise price of $14.31 per share, equal to the Nasdaq closing price on September 1, 2026, the Grant Date. These options vest 25% on the first anniversary of the Grant Date and monthly in 36 equal installments thereafter, subject to continued service. The employees also received an aggregate of 6,440 restricted stock units, vesting 25% annually over four years from the Grant Date, subject to continued service. The awards were granted outside stockholder-approved equity plans, approved by the board’s independent compensation committee, and are intended as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).